Evidence map›Paper›PMID 38978333›Full record

ArticleCancer medicine2024

Guanylate binding protein 5 is an immune-related biomarker of oral squamous cell carcinoma: A retrospective prognostic study with bioinformatic analysis.

Masayo Hasegawa, Yusuke Amano, Atsushi Kihara, Daisuke Matsubara, Noriyoshi Fukushima, Hideyuki Takahashi, Kazuaki Chikamatsu, Hiroshi Nishino, Yoshiyuki Mori, Naohiro Yoshida and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Masayo HasegawaDepartment of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Yusuke AmanoDepartment of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.ORCID 0000-0002-4056-3487
Atsushi KiharaDepartment of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Daisuke MatsubaraDepartment of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Noriyoshi FukushimaDepartment of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Hideyuki TakahashiDepartment of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Kazuaki ChikamatsuDepartment of Otolaryngology-Head and Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Hiroshi NishinoDepartment of Otolaryngology-Head and Neck Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Yoshiyuki MoriDepartment of Dentistry, Oral and Maxillofacial Surgery, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Naohiro YoshidaDepartment of Otolaryngology-Head and Neck Surgery, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Toshiro NikiDepartment of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.

Funding

Japan Society for the Promotion of Science 19K10094
6 · The paper itself

Abstract

backgroundCancer utilizes immunosuppressive mechanisms to create a tumor microenvironment favorable for its progression. The purpose of this study is to histologically characterize the immunological properties of the tumor microenvironment of oral squamous cell carcinoma (OSCC) and identify key molecules involved in the immunological microenvironment and patient prognosis.

methodsFirst, overlapping differentially expressed genes (DEGs) were screened from OSCC transcriptome data in public databases. Correlation analysis of DEGs with known immune-related genes identified genes involved in the immune microenvironment of OSCC. Next, stromal patterns of tumor were classified and immunohistochemical staining was performed for immune cell markers (CD3, CD4, Foxp3, CD8, CD20, CD68, and CD163), programmed death-ligand 1 (PD-L1), and guanylate binding protein 5 (GBP5) in resected specimens obtained from 110 patients with OSCC who underwent resection. Correlations between each factor and their prognostic impact were analyzed.

resultsAmong the novel OSCC-specific immune-related genes screened (including ADAMDEC1, CXCL9, CXCL13, DPT, GBP5, IDO1, and PLA2G7), GBP5 was selected as the target gene. Histopathologic analysis showed that multiple T-cell subsets and CD20-positive cells were less common in the advanced stages, whereas CD163-positive cells were more common in advanced stages. The immature type in the stromal pattern category was associated with less immune cell infiltration, lower expression of PD-L1 in immune cells, lower expression of GBP5 in the stroma, and shorter overall survival and recurrence-free survival. Expression of GBP5 in the tumor and stroma correlated with immune cell infiltration of tumors and PD-L1 expression in tumor and immune cells. Patients with low tumor GBP5 expression and high stromal expression had significantly longer overall survival and recurrence-free survival.

conclusionsThe stromal pattern category may reflect both invasive and immunomodulatory potentials of cancer-associated fibroblasts in OSCC. GBP5 has been suggested as a potential biomarker to predict the prognosis and therapeutic efficacy of immune checkpoint inhibitors.

Indexed as

Biomarkers, TumorComputational BiologyMouth NeoplasmsTumor MicroenvironmentAdultAgedB7-H1 AntigenCarcinoma, Squamous CellFemaleGene Expression Regulation, NeoplasticGTP-Binding ProteinsHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisB7-H1 AntigenBiomarkers, TumorGBP5 protein, humanGTP-Binding ProteinsGBP5OSCCPD‐L1stromal pattern

Identifiers

PMID38978333
PMCPMC11231040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.